Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

Avion Pharmaceuticals LLC specializes in women?s health, pediatrics, and cardiology. Its products include prescription prenatal dietary supplements, prescription iron supplements, dermatology, and oral contraception. The company is headquartered in Alpharetta, GA.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

DepoMed Development Ltd, part of Assertio Holdings, Inc., is a Bermudian company that develops and provides clinical trials on proprietary products for the medical industry.

Suzhou Huatest Biotechnology Co., Ltd., established on 2011-02-28, The scope of business includes R&D and manufacturing of experimental analysis and testing instruments;medicine,Biological product,hygiene products,cosmetic,Nutrients,baby food,disinfectant,pesticide,insecticide,Chinese herbal medicine,dressing material,medical materials,Medical and health products,Medical and Health Instruments,Medical Devices and Equipment,Research and development of animal feeding and breeding technology;Provide technical services for the above related technical projects and scientific research projects;Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA.

Beijing CoSci Med-Tech Co.,Ltd, is a newly developed the research of the pharmaceutical company and an innovative high-tech enterprise subordinated to Beijing Zhongguancun Science and Technology Park.It focuses on preclinical,clinical,early phase drug development and industralizaton research.The company team is made up of veterans from the pharmaceutical industry,prominent scientific experts,and successful business executives.They offer the resoures and the customer-oriented culture for the client from the world to assist to bring the best value for their products. CoSci Med-Tech is at the forefront of the design and the development of sustained-release technique, controlled-release technique and orally disintegrating techniques in China. These technologies are the foundation of their proprietary products.Since CoSci-Med was established,it has provided highly efficient development programs and good market prospects for the drugs and nutritional supplements. By 2009, Cosci Med-Tech co., Ltd has done important work as carrying out theirthe research,development and introduce of new products new technology and establishing strategic partnerships.The company have achieved the registration for the first pharmaceutical prepations from China in EU and developed 80 drug products, applied 107 patents , of which 53 patents have been granted,6 PCTs No matter what type of pharmacologic agent you are working with,CoSci Med-Tech has the capability to support you from development,registration to marketing.We have collaborated with several primary pharmaceutical enterprises at home and abroad. We serve drugs and nutritional supplements client all over the world.We offer programs that are custom designed to meet our clients’ unique situations and needs. CoSci Med-Tech would like to combine its own advantages in helping the foreign businesses to import new products and new technologies ,taking commission processing and open up the big market of China.At the same time,the company can help the China businesses to output new products and new technology into abroad.Abiding the business idea :foundations is in science and technology, honesty is first, cooperation and development,the company would like to carry out active cooperation with the research institutes and universities,pharmaceutical enterprises,medicine distibutors of all countries in the world,and to make contribution to the health of the whole mankind in dedication to their common cause.

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

Established in 1987, Korea United Pharm. Inc. has continued to develop as a pharmaceutical company with its slogan of "Korean owned multinational pharmaceutical company." We have continuously launched new pharmaceutical drugs such as Cilostan CR Tab, Gastiin CR Tab, Clanza CR Tab and etc., through prestigious R&D investment, abundant know-hows and top expert researchers and have been placed as a strong competitor in the pharmaceutical drug development industry. they were named one of Asia's 200 most promising companies by the US economy magazine Forbes.

Part of Lunan Pharmaceutical Group Co., Ltd., Shandong New Time Pharmaceutical Co. Ltd. is a Chinese company located in Linyi that manufactures pharmaceutical products.

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, trading symbol NWRN.

Pharma Two B develops clinically differentiated and value-added products, based on approved drugs. They focus on Fixed-Dose-combinations of two or more drugs with complementary and synergistic effects, providing high clinical value and shorter regulatory pathways (US 505b2 approach). The company develops products in two therapeutic areas with great unmet needs - Parkinson's disease (PD) and Cancer.

Suzhou Farmer Biotechnology Co., Ltd., established on 2011-03-02, Business scope includes biological products,medicine,Pharmaceutical Intermediates,Research and development of medical software and provide related technical consultation;Pharmaceutical Enterprise Management Consulting,Economic Information Consulting,Enterprise Marketing Planning and Development of Environmental Protection Technology;Non-hazardous chemical products,Pharmaceutical software sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Operates as a non-classified establishment

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Zhejiang Meihua Dingchang Pharmaceutical Technology Co., Ltd., established on 2011-09-30, Business scope includes general items:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class II Medical Devices;Sales of Class I Medical Devices;Production of Class I Medical Devices;Disinfectant sales(Free of Hazardous Chemicals);Cosmetics Wholesale;Cosmetics Retail;Daily necessities sales;Pharmaceutical commissioned production;Technology Import and Export;Import and export(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Production of Class III Medical Devices;Class III medical device business;Production of Class II Medical Devices;pharmaceutical production;Disinfectant production(Free of Hazardous Chemicals);Cosmetic production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Beijing Silian Pharmaceutical Co., Ltd. is a private company headquartered in Beijing, China. The firm produces, manufactures and sells folic acid for maternal and child health.

Zhiyao (Shanghai) Pharmaceutical Technology Co., Ltd., established on 2011-07-27, The scope of business includes engaging in medical equipment,medicine,Biotechnology,medical materials,medical reagent,Healthy food,cosmetic,Technology development in the field of daily necessities,technical consulting,Technical Services,technology transfer(human stem cells,Except for the development and application of genetic diagnosis and treatment technology,Steaming of Chinese Herbal Pieces,saute,broil,Except for the application of processing techniques such as calcining),Investment Advisory,Business Management Consulting,Class I medical device,Laboratory equipment,Mechanical equipment and parts,electronic product,Wholesale of electrical appliances,import and export,commission agent(except auction),and provide related services(Commodities that do not involve state trade management,Quota involved,of license-managed goods,According to the relevant regulations of the country). [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]